Hansa Biopharma AB (publ) at its Annual General Meeting held on June 30, 2022 Peter Nicklin as a new member of the Board of Directors for the period until the end of the next Annual General Meeting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.32 SEK | +0.44% | -6.76% | +4.27% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.27% | 137M | |
+1.91% | 42.59B | |
+8.63% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+9.11% | 24.81B | |
-24.43% | 18.17B | |
+28.93% | 12.05B | |
-2.66% | 11.7B | |
+7.09% | 11.1B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB Appoints Peter Nicklin as A New Member of the Board of Director